Prevalence and predictors of potential drug-drug interactions

• Authors: Bozana Nikolic , Slobodan Jankovic , Oliver Stojanov , Jovan Popovic
• Languages of publication: EN

Abstracts

EN

Keywords

EN

Drug-drug interactions; Prevalence; Predictors

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2014
• Volume: 9
• Issue: 2
• Pages: 348-356

Dates

published

1 - 4 - 2014

online

13 - 2 - 2014

Contributors

author

Bozana Nikolic

author

Slobodan Jankovic

• Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34000, Kragujevac, Serbia

author

Oliver Stojanov

author

Jovan Popovic

• Department of Pharmacology and Toxicology, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21000, Novi Sad, Serbia

References

• [1] Michalets E.L., Williams C.R., Drug interactions with cisapride: clinical implications, Clin. Pharmacokinet., 2000, 39, 49–75 http://dx.doi.org/10.2165/00003088-200039010-00004[Crossref]
• [2] Juntti-Patinen L., Neuvonen P.J., Drug-related deaths in a university central hospital, Eur. J. Clin. Pharmacol., 2002, 58, 479–482 http://dx.doi.org/10.1007/s00228-002-0501-2[Crossref]
• [3] Pirmohamed M., James S., Meakin S., Green C., Scott A.K., Walley T.J., et al., Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients, BMJ., 2004, 329, 15–19 http://dx.doi.org/10.1136/bmj.329.7456.15
• [4] Zed P.J., Abu-Laban R.B., Balen R.M., Loewen P.S., Hohl C.M., Brubacher J.R., et al., Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study, CMAJ., 2008, 178, 1563–1569 http://dx.doi.org/10.1503/cmaj.071594[Crossref]
• [5] Patel P., Zed P.J., Drug-related visits to the emergency department: how big is the problem?, Pharmacotherapy, 2002, 22, 915–923 http://dx.doi.org/10.1592/phco.22.11.915.33630[Crossref]
• [6] Guédon-Moreau L., Ducrocq D., Duc M.F., Quieureux Y., L’Hôte C., Deligne J., et al., Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999, Eur. J. Clin. Pharmacol., 2003, 59, 689–695 http://dx.doi.org/10.1007/s00228-003-0684-1[Crossref]
• [7] Huang S.M., Lesko L.J., Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned?, J. Clin. Pharmacol. 2004, 44, 559–569 http://dx.doi.org/10.1177/0091270004265367[Crossref]
• [8] Moura C.S., Acurcio F.A., Belo N.O., Drug-drug interactions associated with length of stay and cost of hospitalization, J. Pharm. Pharm. Sci., 2009, 12, 266–272
• [9] Einarson T.R., Metge C.J., Iskedjian M., Mukherjee J., An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutarylcoenzyme A reductase inhibitors on health care utilization: a Canadian population-based study, Clin. Ther. 2002, 24, 2126–2136 http://dx.doi.org/10.1016/S0149-2918(02)80102-3[Crossref]
• [10] Saurat J.H., Guérin A., Yu A.P., Latremouille-Viau D., Wu E.Q., Gupta S.R., et al., High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice, Dermatology, 2010, 220, 128–137 http://dx.doi.org/10.1159/000275198[Crossref]
• [11] Pergolizzi J.V. Jr., Labhsetwar S.A., Amy Puenpatom R., Ben-Joseph R., Ohsfeldt R., Summers K.H., Economic impact of potential CYP450 pharmacokinetic drug-drug interactions among chronic low back pain patients taking opioids, Pain Pract., 2012, 12, 45–56 http://dx.doi.org/10.1111/j.1533-2500.2011.00503.x[Crossref]
• [12] Pergolizzi J.V. Jr., Labhsetwar S.A., Puenpatom R.A., Ben-Joseph R., Ohsfeldt R., Summers K.H., Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioids, Pain Pract., 2012, 12, 33–44 http://dx.doi.org/10.1111/j.1533-2500.2011.00498.x[Crossref]
• [13] Hamilton R.A., Briceland L.L., Andritz M.H., Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population, Pharmacotherapy, 1998, 18, 1112–1120
• [14] Obreli-Neto P.R., Nobili A., de Oliveira Baldoni A., Guidoni C.M., de Lyra Junior D.P., Pilger D., et al., Adverse drug reactions caused by drug-drug interactions in elderly outpatients: a prospective cohort study, Eur. J. Clin. Pharmacol., 2012, 68, 1667–1676 http://dx.doi.org/10.1007/s00228-012-1309-3[Crossref]
• [15] van Roon E.N., Flikweert S., le Comte M., Langendijk P.N., Kwee-Zuiderwijk W.J., Smits P., et al., Clinical relevance of drug-drug interactions: a structured assessment procedure, Drug Saf., 2005, 28, 1131–1139 http://dx.doi.org/10.2165/00002018-200528120-00007[Crossref]
• [16] Tatro D.S., Drug Interaction Facts? 2012 - The authority on drug interactions, Facts and Comparasions, St. Louis, Wolters Kluwer Health, 2011
• [17] Aparasu R., Baer R., Aparasu A., Clinically important potential drug-drug interactions in outpatient settings, Res. Social. Adm. Pharm., 2007, 3, 426–437 http://dx.doi.org/10.1016/j.sapharm.2006.12.002[Crossref]
• [18] Grönroos P.E., Irjala K.M., Huupponen R.K., Scheinin H., Forsström J., Forsström J.J., A medication database a tool for detecting drug interactions in hospital, Eur. J. Clin. Pharmacol., 1997, 53, 13–17 http://dx.doi.org/10.1007/s002280050330[Crossref]
• [19] Merlo J., Liedholm H., Lindblad U., Björck-Linné A., Fält J., Lindberg G., et al., Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999: cross sectional study, BMJ., 2001, 323, 427–428 http://dx.doi.org/10.1136/bmj.323.7310.427[Crossref]
• [20] Bergendal L., Friberg A., Schaffrath A., Potential drug-drug interactions in 5125 mostly elderly outpatients in Gothenburg, Sweden, Pharm. World Sci., 1995, 17, 152–157 http://dx.doi.org/10.1007/BF01879709[Crossref]
• [21] Costa A.J., Potential drug interactions in an ambulatory geriatric population, Fam. Pract., 1991, 8, 234–236 http://dx.doi.org/10.1093/fampra/8.3.234[Crossref]
• [22] Obreli Neto P.R., Nobili A., Marusic S., Pilger D., Guidoni C.M., Baldoni Ade O., et al., Prevalence and predictors of potential drug-drug interactions in the elderly: a cross-sectional study in the brazilian primary public health system, J. Pharm. Pharm. Sci., 2012, 15, 344–354
• [23] Björkman I.K., Fastbom J., Schmidt I.K., Bernsten C.B., Pharmaceutical Care of the Elderly in Europe Research (PEER) Group, Drug-drug interactions in the elderly, Ann. Pharmacother., 2002, 36, 1675–1681 http://dx.doi.org/10.1345/aph.1A484[Crossref]
• [24] Janchawee B., Wongpoowarak W., Owatranporn T., Chongsuvivatwong V., Pharmacoepidemiologic study of potential drug interactions in outpatients of a university hospital in Thailand, J. Clin. Pharm. Ther., 2005, 30, 13–20 http://dx.doi.org/10.1111/j.1365-2710.2004.00598.x[Crossref]
• [25] Cruciol-Souza J.M., Thomson J.C., Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital, J. Pharm. Pharm. Sci., 2006, 9, 427–433
• [26] Doubova-Dubova S.V., Reyes-Morales H., Torres-Arreola Ldel P., Suárez-Ortega M., Potential drugdrug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City, BMC. Health Serv. Res., 2007, 7, 147 http://dx.doi.org/10.1186/1472-6963-7-147[Crossref]
• [27] Nobili A., Pasina L., Tettamanti M., Lucca U., Riva E., Marzona I., et al., Potentially severe drug interactions in elderly outpatients: results of an observational study of an administrative prescription database, J. Clin. Pharm. Ther., 2009, 34, 377–386 http://dx.doi.org/10.1111/j.1365-2710.2009.01021.x[Crossref]
• [28] Lin C.F., Wang C.Y., Bai C.H., Polypharmacy, aging and potential drug-drug interactions in outpatients in Taiwan: a retrospective computerized screening study, Drugs Aging, 2011, 28, 219–225 http://dx.doi.org/10.2165/11586870-000000000-00000[Crossref]
• [29] Bjerrum L., Andersen M., Petersen G., Kragstrup J., Exposure to potential drug interactions in primaryhealth care, Scand. J. Prim. Health Care., 2003, 21, 153–158 http://dx.doi.org/10.1080/02813430310001806[Crossref]
• [30] Johnell K., Klarin I., The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600000 elderly patients from the Swedish Prescribed Drug Register, Drug Saf., 2007, 30, 911–918 http://dx.doi.org/10.2165/00002018-200730100-00009[Crossref]
• [31] Gagne J.J., Maio V., Rabinowitz C., Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy, J. Clin. Pharm. Ther., 2008, 33, 141–151 http://dx.doi.org/10.1111/j.1365-2710.2007.00891.x[Crossref]
• [32] Janchawee B., Owatranporn T., Mahatthanatrakul W., Chongsuvivatwong V., Clinical drug interactions in outpatients of a university hospital in Thailand, J. Clin. Pharm. Ther., 2005, 30, 583–590 http://dx.doi.org/10.1111/j.1365-2710.2005.00688.x[Crossref]
• [33] Carthy P., Harvey I., Brawn R., Watkins C., A study of factors associated with cost and variation in prescribing among GPs, Fam. Pract., 2000, 17, 36–41 http://dx.doi.org/10.1093/fampra/17.1.36[Crossref]
• [34] Rahmner P.B., Gustafsson L.L., Larsson J., Rosenqvist U., Tomson G., Holmström I., Variations in understanding the drug-prescribing process: a qualitative study among Swedish GPs, Fam. Pract., 2009, 26, 121–127 http://dx.doi.org/10.1093/fampra/cmn103[Crossref]
• [35] Wun Y.T., Chan C.S., Dickinson J.A., Determinants of physicians’ attitude towards prescribing, J. Clin. Pharm. Ther., 2002; 27, 57–65 http://dx.doi.org/10.1046/j.1365-2710.2002.00389.x[Crossref]
• [36] WHO Collaborating Centre for Family of International Classifications. International Classification of Diseases. Available from: http://www.who.int/classifications/icd/en/ Accessed: 2012 December
• [37] WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index. Available from: http://www.whocc.no/atc_ddd_index/ Accessed: 2012 December
• [38] Fulda T.R., Valuck R.J., Zanden J.V., Parker S., Byrns P.J., Disagreement among drug compendia on inclusion and ratings of drug-drug interactions, Curr. Ther. Res., 2000, 61, 540–548 http://dx.doi.org/10.1016/S0011-393X(00)80036-3[Crossref]
• [39] Vitry A.I., Comparative assessment of four drug interaction compendia, Br. J. Clin. Pharmacol., 2007, 63, 709–714 http://dx.doi.org/10.1111/j.1365-2125.2006.02809.x[Crossref]
• [40] Rätz-Bravo A.E., Tchambaz L., Krähenbühl-Melcher A., Hess L., Schlienger R.G., Krähenbühl S., Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy, Drug Saf., 2005, 28, 263–275 http://dx.doi.org/10.2165/00002018-200528030-00007[Crossref]
• [41] Chatsisvili A., Sapounidis I., Pavlidou G., Zoumpouridou E., Karakousis V.A., Spanakis M., et al., Potential drug-drug interactions in prescriptions dispensed in community pharmacies in Greece, Pharm. World Sci., 2010, 32, 187–193 http://dx.doi.org/10.1007/s11096-010-9365-1[Crossref]
• [42] Jones J.D., Mogali S., Comer S.D., Polydrug abuse: a review of opioid and benzodiazepine combination use, Drug Alcohol Depend., 2012, 125, 8–18 http://dx.doi.org/10.1016/j.drugalcdep.2012.07.004[Crossref]
• [43] Gelkopf M., Bleich A., Hayward R., Bodner G., Adelson M., Characteristics of benzodiazepine abuse in methadone maintenance treatment patients: a 1 year prospective study in an Israeli clinic, Drug Alcohol Depend., 1999, 55, 63–68 http://dx.doi.org/10.1016/S0376-8716(98)00175-6
• [44] Stitzer M.L., Griffiths R.R., McLellan A.T., Grabowski J., Hawthorne J.W., Diazepam use among methadone maintenance patients: patterns and dosages, Drug Alcohol Depend., 1981, 8, 189–199 http://dx.doi.org/10.1016/0376-8716(81)90061-2[Crossref]
• [45] Teixeira J.J., Crozatti M.T., dos Santos C.A., Romano-Lieber N.S., Potential drug-drug interactions in prescriptions to patients over 45 years of age in primary care, southern Brazil, PloS One, 2012, 7, e47062 http://dx.doi.org/10.1371/journal.pone.0047062[Crossref]
• [46] Secoli S.R., Figueras A., Lebrão M.L., de Lima F.D., Santos J.L., Risk of potential drug-drug interactions among Brazilian elderly: a populationbased, cross-sectional study, Drugs Aging, 2010, 27, 759–770 http://dx.doi.org/10.2165/11538460-000000000-00000[Crossref]
• [47] Rosholm J.U., Bjerrum L., Hallas J., Worm J., Gram L.F., Polypharmacy and the risk of drug-drug interactions among Danish elderly. A prescription database study, Dan. Med. Bull., 1998, 45, 210–213
• [48] Hohl C.M., Dankoff J., Colacone A., Afilalo M., Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department, Ann. Emerg. Med., 2001, 38, 666–671 http://dx.doi.org/10.1067/mem.2001.119456[Crossref]
• [49] Rambhade S., Chakarborty A., Shrivastava A., Patil U.K., Rambhade A., A survey on polypharmacy and use of inappropriate medications, Toxicol. Int., 2012, 19, 68–73 http://dx.doi.org/10.4103/0971-6580.94506[Crossref]
• [50] Reason B., Terner M., Moses McKeag A., Tipper B., Webster G., The impact of polypharmacy on the health of Canadian seniors, Fam. Pact., 2012, 29, 427–432 http://dx.doi.org/10.1093/fampra/cmr124[Crossref]
• [51] Veehof L.J., Stewart R.E., Meyboom-de Jong B., Haaijer-Ruskamp F.M., Adverse drug reactions and polypharmacy in the elderly in general practice, Eur. J. Clin. Pharmacol., 1999, 55, 533–536 http://dx.doi.org/10.1007/s002280050669[Crossref]
• [52] Lopez-Picazo J.J., Ruiz J.C., Sanchez J.F., Ariza A., Aguilera B., Lazaro D., et al., Prevalence and typology of potential drug interactions occuring in primary care patients, Eur. J. Gen. Pract., 2010, 16, 92–99 http://dx.doi.org/10.3109/13814788.2010.481709[Crossref]
• [53] Sloan R.W., Drug interactions, Am. Fam. Physician, 1983, 27, 229–238

Identifiers

DOI

10.2478/s11536-013-0272-4